Gan & Lee Pharmaceuticals, a biopharmaceutical company specializing in insulin and insulin analogues in China, announced that it has entered into an agreement to commercialize three insulin analogs to Sandoz, a division of Swiss drugmaker Novartis with a focus on biosimilar pharmaceuticals.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?